Cumulative Live Birth Rates for Low-Prognosis Women Over 5 Years or 9 Frozen-Thawed Embryo Transfer Cycles

Di Di Chen
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University

Xi Shen
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University

Li Wang
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University

Yanping Kuang (KUANGYP1506@sh9hospital.org.cn)
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University

Research Article

Keywords: cumulative live birth rate, low prognosis, poor ovarian response, POSEIDON criteria, freeze-all strategy

Posted Date: January 3rd, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1150457/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at BMC Pregnancy and Childbirth on March 22nd, 2022. See the published version at https://doi.org/10.1186/s12884-022-04511-7.
Abstract

Background: For heterogeneous populations of low-prognosis women, it remains unclear as to how long individuals should continue undergoing ART when attempting to have a baby, as there have been insufficient studies to date tracking the cumulative live birth rates (CLBRs) for these women over the entire course of their ART treatment, particularly over extended time periods.

Methods: This was a retrospective analysis of 17,698 women at a tertiary care academic medical center who had begun undergoing IVI/ICSI cycles using a PPOS approach between January 2013 and January 2019. Low-prognosis patients were stratified into four groups based upon POSEIDON criteria, with patients exhibiting normal or high ovarian reserves and response to stimulation (defined as AFC $\geq 5$, $>9$ oocytes retrieved) being included as controls (group 5). The CLBR within 5 years or 9 FET cycles from the OPU day of the first cycle was the primary endpoint for this study, including all repetitive oocyte retrieval cycles and subsequent FET cycles. Optimistic and conservative approaches were used for the analysis of CLBRs and the depiction of cumulative incidence curves.

Results: Under both optimistic and conservative model analyses, patients in group 5 exhibited the highest CLBR within 5 years or 9 FET cycles, followed by POSEIDON group 1, group 3, group 2, and group 4. Upward trends in CLBRs were evident across the five groups with the prolongation of time or an increase in FET cycle counts. Within the first 2 years or 3 FET cycles, the CLBRs rose rapidly, followed by more moderate increases over the following 2-3.5 years or 4-6 cycles, with the patients in group 3 and group 4 exhibiting the most obvious improvements. Patients in all groups reached a CLBR plateau after 3.5 years or 6 FET cycles.

Conclusions: All low-prognosis women should undergo ART treatment for a minimum of 2 years or 3 FET cycles, and exhibit better outcomes when extending ART treatment to 3.5 years or 6 FET cycles (particularly for POSEIDON groups 3 and 4), but should consider ceasing further treatment thereafter due to a lack of apparent benefit.

Background

Low prognosis is a concept derived from the poor ovarian response (POR) classification that seeks to better differentiate between POR patients and those with a diminished ovarian reserve (DOR). POR patients undergoing assisted reproductive technology (ART)-based interventions typically exhibit low ovarian reserves and poor ovarian responses to exogenous gonadotropin stimulation, together with high cancellation rates and low rates of resultant pregnancy (1, 2). In most cases, researchers focus on assessing ART clinical outcomes including odds of pregnancy and delivery on a per-cycle or per-transfer basis (3), and these approaches are not well-suited to comprehensively evaluating outcomes among POR patients that have undergone repeated oocyte retrieval cycles in order to store sufficient embryos for subsequent transfers(4). The most important outcome for POR patients is the overall chance of a live birth after multiple attempts. As such, the cumulative live birth rate (CLBR) (3, 5), which can track long-term clinical outcomes, has been proposed to be the optimal metric for use when evaluating clinical results associated with the entirety of an ART treatment course.

Previous studies reporting CLBRs have been subject to several limitations. Some have failed to include in vitro fertilization (IVF) cycles involving frozen embryo transfer(6–8), while others have failed to report live-birth
rates, including multiple deliveries, as their primary outcomes. Moreover, other studies have calculated cumulative success rates over multiple IVF cycles by adding together rates from different cycles. Currently, CLBR values for a given patient are typically calculated from their first ovarian stimulation, and these rates include the subsequent fresh embryo transfer (ET) and/or frozen embryo transfer (FET) necessary to achieve a minimum of one live fetus as an outcome. These criteria are increasingly relevant given the growing frequency of freeze-thaw transfer approaches. To date, however, there have been few studies exploring CLBRs among low-prognosis women undergoing a ‘freeze-all’ transfer strategy, particularly over extended periods of time. The present study was thus conducted to offer a more accurate, evidence-based approach to estimating the odds that POR women will experience a live birth when undergoing ART.

The heterogeneity of POR patient populations poses a challenge to diagnosing and treating these individuals. While POR patients were classified according to the first consensus diagnostic criteria - the “Bologna criteria” - by the European Society of Human Reproduction and Embryology (ESHRE) in 2011, many patient categories with potentially different prognostic outcomes may arise within these minimum criteria. As such, in 2015, the POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) group introduced a new system for the stratification of infertility patients exhibiting expected or unexpected responses to exogenous gonadotropins. These POSEIDON criteria stratify POR patients according to heterogeneous characteristics, spurring a shift away from POR terminology and towards the concept of low-prognosis patients, allowing for the more precise classification of patients according to different diagnostic criteria and the mapping of optimal treatments for different patient subpopulations.

In the present retrospective study, low-prognosis patients undergoing a PPOS protocol combined with a freeze-all strategy were grouped according to POSEIDON criteria, and CLBRs within 5 years or 9 FET cycles were compared among patients in different POSEIDON groups. The goal of this study was to determine the odds that a low-prognosis woman will achieve a live birth when undergoing ART and at what point those women should cease undergoing ART attempts. Optimistic and conservative analyses were employed to compare CLBRs among these four POSEIDON groups for up to 5 years or 9 FET cycles, with the goal of formulating individualized treatment recommendations based on analyses of a large population of low-prognosis women undergoing ART treatment.

Methods

Study setting and patients

This retrospective study was conducted at the Department of Assisted Reproduction of the Ninth People’s Hospital of Shanghai Jiao Tong University School of Medicine, and included 17,698 women. The study protocol was approved by the hospital’s Ethics Committee (Institutional Review Board). Included patients underwent an initial IVF / intracytoplasmatic sperm injection (ICSI) cycle using a PPOS strategy between January 2013 and January 2019. All patient cycles using a PPOS cycle were followed through August 2020 or until a live birth had been achieved. Low-prognosis patients were categorized into 4 groups according to their age, antral follicle count (AFC), and oocytes retrieved in the first cycle as per the POSEIDON criteria as follows: Group 1 (younger unexpected poor responders): age < 35 years, normal ovarian reserve (AFC ≥ 5), ≤ 9
oocytes retrieved after standard ovarian stimulation in the first cycle; Group 2 (older unexpected poor responders): age ≥ 35 years, normal ovarian reserve (AFC ≥ 5), ≤ 9 oocytes retrieved after standard ovarian stimulation in the first cycle; Group 3 (younger expected poor responders): age < 35 years, poor ovarian reserve (AFC < 5); and Group 4 (older expected poor responders): age ≥ 35 years, poor ovarian reserve (AFC < 5) (31). Patients with normal or high ovarian reserves and responses to stimulation (AFC ≥ 5, retrieved oocytes > 9) (34) were enrolled as a control group (group 5). Women that underwent treatment with donor semen or that did not undergo subsequent frozen embryo transfers were excluded from this study.

**PPOS and frozen-embryo transfer protocols**

Patients were administered hMG (150-225IU; Anhui Fengyuan Pharmaceutical Co, China) and oral P from MC3 onward. Oral P included medroxyprogesterone acetate (MPA, 4-10mg/d, Beijing Zhong Xin Pharmaceutical, China), Utrogestan (200mg/d, Laboratories Besins International, Paris, France), and oral Duphaston (DYG, 20 mg/d, Abbott Biologicals B.V., Netherlands) (35-38). The dosage of P was adjusted based upon ultrasound examinations and analyses of serum hormone levels on the same day as follicular monitoring. When more than three dominant follicles (≥ 18 mm in diameter) were evident, the final stage of oocyte maturation was triggered by a single use of the final stage of oocyte maturation was triggered by a single dose (hCG, 5,000-10,000 IU, Lizhu Pharmaceutical Trading Co.) or a dual trigger consisting of a low dose of hCG (1,000 IU) and Decapeptyl (0.1 mg, Ferring International Center SA, Germany) (37-39).

Transvaginal ultrasound-guided oocyte retrieval was conducted 35-39 hours after trigger (40). All follicles > 10 mm in diameter were aspirated, with fertilization being achieved via conventional IVF or ICSI, depending on semen quality (41). As per Cummins’ standard (42), good quality embryos were defined as grade I and II embryos with at least 8 cells on day 3 after oocyte retrieval. Other embryos (non-top-quality embryos) were cultured to the blastocyst stage, with good-quality embryos and the good morphology blastocysts being selected for vitrification (39).

Endometrial preparation was conducted as in prior reports (43). Briefly, natural cycles were employed for patients with a regular menstrual cycle, while hormone therapy or stimulation cycles were employed for patients with irregular menstrual cycles (44). One or two embryos were transferred per cycle, with progesterone supplementation being maintained through 8 weeks if pregnancy was confirmed.

**Statistical analysis**

The CLBR of patients within 5 years from their ovum pick-up (OPU) day in the first cycle was the primary outcome for the present study, including all repetitive oocyte retrieval cycles and subsequent FET cycles (16). Baseline characteristics were analyzed based upon data during the first oocyte retrieval cycle for each patient conducted using a progestin-primed ovarian stimulation (PPOS) protocol in our center. Ongoing pregnancies were assessed at 4 and 6 weeks after FET by ultrasound-mediated gestational sac and fetal heartbeat detection. Live birth was defined as any birth event in which at least one baby was born alive (18). When patients achieved multiple live births, only the first conception event was considered for the present study. Cumulative incidence curves were utilized to assess CLBR by time and FET cycles (45).
To account for ART treatment discontinuation, we employed two evaluation approaches (17, 45). The optimistic analysis approach assumed that patients who stop treatment would have the same chances of pregnancy as those who continue treatment. This approach, however, has the potential to overestimate the true odds of conception following multiple successive IVF treatments. The conservative competing risk approach, in contrast, assumed that patients who discontinue ART treatment would have a live-birth rate of zero. The actual values will inevitably fall between these two extremes (16, 46). Differences between these groups were compared with an adjusted pairwise log-rank test.

SPSS v23.0 (SPSS Inc., IL, USA) was used to conduct all statistical analyses. Chi-squared tests and one-way ANOVAs were used to compare categorical and continuous variables, respectively. Patient characteristics are given as percentages or means with standard deviations (SD). P < 0.05 was the threshold of significance. CLBR curves with 95% confidence intervals (95% CIs) were calculated using R (v 1.4.1106; R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient demographics and baseline characteristics

The overall study flow diagram is shown in Figure 1. In total, 17,698 patients were separated into five groups: POSEIDON group 1 (younger unexpected poor responders, n=4470), POSEIDON group 2 (older unexpected poor responders, n=2270), POSEIDON group 3 (younger expected poor responders, n=1110), POSEIDON group 4 (older expected poor responders, n=1095), and group 5 (control group, n=8753). Patients in the control group exhibited a sufficient ovarian reserve (AFC ≥ 5) and a sufficient number of oocytes retrieved (> 9) during the first ovarian retrieval cycle. Patient demographics and baseline characteristics are shown in Table 1.

When patients were grouped according to POSEIDON criteria (Table 1), the average ages of the older patients in group 2 (38.01±2.83) and group 4 (39.37±3.38) were notably higher than those of younger patients in group 1 (30.21±2.76), group 3 (30.32±2.71), and the control group (30.44±3.85). Consistent with grouping criteria, the average AFC of expected poor responders in group 3 (2.19±1.65) and group 4 (2.51±1.32) was significantly lower than that of group 1 (11.17±5.77), group 2 (8.99±4.09), and control group patients (15.24±6.21). Average numbers of oocytes retrieved during the first cycle were highest in the control group (16.84±6.57), followed by group 3 (7.07±6.67), group 1 (5.97±2.31), group 2 (5.27±2.34), and group 4 (3.29±3.05). Owing to heterogeneity among low-prognosis women, types of infertility, primary etiology, and BMI all differed significantly among these five groups (P<0.05). Furthermore, with increasing age, the duration of infertility rose group 1 (2.93±2.42) to group 3 (3.14±2.46), group 2 (4.08±3.96), and group 4 (4.32±4.56). Gravidity, parity, and year of treatment also differed significantly among these groups (P<0.05).

Ovarian stimulation characteristics and pregnancy outcomes

As expected, patients in group 4 (older expected poor responders) underwent the most oocyte retrieval cycles (1.97 ± 1.33), followed by patients in group 3 (younger expected poor responders, 1.55 ± 0.94), group 2 (older unexpected poor responders, 1.54 ± 0.89), and group 1 (younger unexpected poor responders, 1.33 ± 0.64), as
shown in Table 2. Patients in the control group underwent the fewest oocyte retrieval cycles (1.11 ± 0.38) (P<0.05). However, the number of retrieved oocytes was smallest in group 4 (3.29±3.05), and increased in group 2 (5.27±2.34), group 1 (5.97±2.31), and group 3 (7.07±6.67), with the greatest number of oocytes having been retrieved for patients in the control group (16.84 ± 6.57) (P<0.05). As such, the oocyte output rate (number of oocytes retrieved / AFC x 100%) (19) was highest in group 3 (younger expected poor responders, 199.21%), followed by group 5 (normal or high responders, 109.28%), group 4 (older expected poor responders, 99.31%), group 2 (older unexpected poor responders, 62.96%), and group 1 (younger unexpected poor responders, 58.02%). Patients in the control group also exhibited the highest number of 2PN (10.39±5.09) and good quality embryos (5.32±3.78) per oocyte retrieval cycle, followed by patients in group 3 (4.47±4.26; 2.38±2.59), group 1 (3.86±2.08; 2.15±1.71), group 2 (3.44±1.95; 1.98±1.55), and group 4 (2.16±2.13; 1.27±1.39) (P<0.05).

Table 2 displays the CLBRs within 2 and 5 years in each group with corresponding 95% CIs. When using the optimistic method, the CLBRs over 2 years were 75.6%, 55.5%, 67.2%, 35.7%, and 76.2% in groups 1-5, respectively. Using the conservative method, the CLBRs over 2 years in groups 1-5 were 63.7%, 42.1%, 55.3%, 25.9%, and 70.5%, respectively. When the CLBR timeframe was extended to five years, similar decreasing trends were observed from group 5 (optimistic: 79.3%; conservative: 72.5%) to group 1 (80.8%; 66.0%), group 3 (75.0%; 58.4%), group 2 (60.3%; 43.6%), and group 4 (41.4%; 27.2%). However, there may be differences in the extent of these CLBRs among these groups over the entirety of this 5-year period. As such, we utilized time-dependent CLBR curves to trace the extent of CLBR improvements in each POSEIDON subgroup.

**Cumulative live birth rates within 5 years**

The cumulative incidence curves and pairwise log-rank comparisons for CLBRs between the optimistic and conservative methods in these five groups are shown in Figure 2. All curves differed significantly among these five groups (P<0.001). Under both the optimistic and conservative analytical methods, patients in all groups exhibited rapid increases in CLBRs within the first 1-2 years, with the CLBR of group 5 (control group) being the highest (optimistic: 76.2%; conservative: 70.5%), followed by that of group 1 (younger unexpected poor responders, optimistic: 75.6%; conservative: 63.7%), group 3 (younger expected poor responders, optimistic: 67.2%; conservative: 55.3%), group 2 (older unexpected poor responders, optimistic: 67.2%; conservative: 42.1%), and group 4 (older expected poor responders, optimistic: 35.7%; conservative: 25.9%).

Over the following 2- to 3.5-year periods, CLBRs in these five groups remained in the same rank-order and rose modestly when analyzed via the optimistic method (control group: 2.6%; group 1: 4.5%; group 3: 7.3%; group 2: 4.6%; group 4: 3.2%), whereas they rose more slowly when assessed via the conservative method (control group: 1.6%; group 1: 1.9%; group 3: 2.8%; group 2: 1.4%, group 4: 0.9%). Within 3.5-5 years, CLBRs in all five groups largely plateaued (control group: 0.5%; group 1: 0.7%; group 3: 0.5%; group 2: 0.2%, group 4: 2.5% with the optimistic method; control group: 0.4%; group 1: 0.4%; group 3: 0.3%; group 2: 0.1%, group 4: 0.4% with the conservative method).

Notably, among these five groups the CLBRs of patients in group 3 (younger expected poor responders) increased most significantly within 2-3.5 years under both the optimistic (7.3%) and conservative (2.8%)
analytical methods. Interestingly, the CLBRs of patients in group 4 (older expected poor responders) also rose notably within the after 3.5-5-year period (optimistic: 2.5%; conservative: 0.4%), whereas the other four groups had largely plateaued by this time point. As the interval between oocyte retrievals or FET cycles differed among patients, this may not accurately reflect upward trends in CLBRs over time among groups. As such, we conducted further analyses of CLBR improvements as a function of the number of FET cycles completed in each of these POSEIDON subgroups.

**Cumulative live birth rates within 9 FET cycles**

Cumulative ongoing birth rates as a function of the number of FET cycles completed, as analyzed via both the conservative and optimistic approaches, are shown in Figure 3. CLBR curves differed significantly among groups with the exception of those for groups 1 and 5 ($P<0.001$). Under both the optimistic and conservative models, patients in these five groups exhibited rapid initial increases in CLBRs within 3 FET cycles, with these CLBRs decreasing from group 5 (control group, optimistic: 83.0%; conservative: 76.2%) to group 1 (younger unexpected poor responders, optimistic: 81.2%; conservative: 67.8%), group 3 (younger expected poor responders, optimistic: 77.1%; conservative: 60.7%), group 2 (older unexpected poor responders, optimistic: 60.5%; conservative: 45.5%), to group 4 (older expected poor responders, optimistic: 38.8%; conservative: 28.2%).

From 4-6 FET cycles, CLBRs in these five groups remained in the same rank-order as above and exhibited modest increases under the optimistic method (control group: 10.7%; group 1: 12.1%; group 3: 10.3% (only 5 FET cycles); group 2: 12.6%; group 4: 16.3%). While in the conservative method, the increase of CLBRs within five groups were extremely slowly (control group: 4.2%; group 1: 2.2%; group 3: 1.4%; group 2: 1.2%; group 4: 1.1%). Then CLBRs of five groups all maintained in their plateaus after 6 FET cycles, no matter in the optimistic or conservative methods.

**Discussion**

For the low-prognosis women, LBR of per embryo transfer cycle or CLBR of all embryos retrieved in the first IVF/ICSI cycle could not reflect their chance of having a live birth in a comprehensive manner. In contrast, the CLBR analyses conducted in this study offer insight into outcomes throughout the entire course of ART treatment, providing more robust guidance for different POSEIDON subgroups of low-prognosis women. Overall, we found that CLBRs for low-prognosis women declined from group 1 (younger unexpected poor responders) to group 3 (younger expected poor responders), group 2 (older unexpected poor responders), and group 4 (older unexpected poor responders) as a function of treatment time or number of FET cycles under both conservative and optimistic analytical methods. While the specific CLBRs in these four POSEIDON subgroups exhibited different trajectories, all low-prognosis women exhibited increases in CLBRs over the first 2 years or 3 FET cycles, and these rates continued to rise moderately from 2-3.5 years or 4-6 FET cycles. After 3.5 years or 6 FET cycles, the CLBRs of all analyzed low-prognosis women largely plateaued. Together, our findings offer insight into the CLBRs of patients in each POSEIDON subgroup over 5 years and 9 FET cycles, providing a valuable reference for clinicians undergoing ART treatment.
Strengths and Limitations

To the best of our knowledge, this study traced the long-term CLBRs of different groups of low-prognosis patients over the longest timespan and the highest number of FET cycles. The CLBR used in this study encompassed all oocyte retrievals and subsequent FET cycles, rather than the pregnancy outcome of the first fresh or frozen embryo transfer cycle (47), with this being distinct from previously reported CLBRs that were only associated with a single oocyte retrieval cycle (19). As such, the CLBR used herein is more comprehensive and objective as a means of assessing pregnancy outcomes among low-prognosis women. Moreover, our application of both optimistic and conservative approaches ensures that our findings will remain robust while appropriately addressing the issue of treatment discontinuation (45).

We additionally explored improvements in CLBR as a function of treatment duration and FET cycle count in different groups of low-prognosis women with heterogeneous characteristics that had been grouped in accordance with POSEIDON criteria. This approach is a powerful strategy capable of offering insight into whether or not indefinite ART treatment will continue to improve CLBRs for these low-prognosis women. Overall, our results demonstrate that all low-prognosis women in all four POSEIDON groups should undergo ART treatment for a minimum of 2 years or 3 FET cycles, and were likely to achieve better outcomes when extending treatment durations to 3.5 years or 6 FET cycles, particularly for women in group 3 (younger expected poor responders) and group 4 (older expected poor responders). However, no groups appeared to benefit substantially from undergoing ART treatment for more than 3.5 years or 6 FET cycles, suggesting that these guidelines can be used to guide counseling and consultation for different groups of low-prognosis women in order to maximize their odds of a live birth while reducing unnecessary and unproductive expenditures.

Despite the abovementioned advantages of our study, it is nonetheless subject to certain limitations. For one, this was a single-center retrospective study. While a large number of FET cycles for low-prognosis women were included in these analyses, the retrospective nature of this research ensures that further validation will be required to confirm these conclusions. Additionally, we did not assess anti-Mullerian hormone (AMH), which is also a predictor of ovarian response, when categorizing women into the expected and unexpected poor responder categories as these data were not present in our database. Moreover, patients in group 3 (younger expected poor responders) only routinely underwent 5 FET cycles in this study, preventing us from fully assessing their improvements in CLBRs in the 4-6 FET cycle range, particularly given that patients in group 4 (older expected poor responders) exhibited striking improvements in CLBRs within 4-6 FET cycles.

Differences between our results and other research

Prior studies of low-prognosis women have often utilized primary outcome indicators such as live birth rates per embryo transfer cycle or cumulative pregnancy rates from a single oocyte retrieval cycle (2, 19, 48, 49). However, for low-prognosis women that exhibit low pregnancy rates (2) and typically require more than one cycle to achieve a live birth (50), the odds of having a baby at any point during the ART treatment process are the most important endpoint of interest. As such, our study adopted cumulative pregnancy rates over multiple ART cycles including all oocyte retrievals and subsequent FET cycles (50, 51), thus emphasizing the
overall pregnancy rates given that these are the most important endpoint for this low-prognosis patient population.

We additionally explored whether low-prognosis patients should continue pursuing ART indefinitely as a means of improving CLBRs by tracing improvements in CLBRs over time or with increases in FET cycle count. Treatment times as long as 5 years were included, as they included all episodes of live birth (including second or greater births) associated with a single round of egg collection(3). It is also important that low-prognosis patients consider how best to balance the completion of multiple rounds of oocyte retrieval for banking purposes with the timely transplantation of fertilized embryos(3, 4). As such, we additionally explored changes in CLBRs with increasing numbers of FET cycles (up to 9 FET cycles). In so doing, we sought to address the question of when clinicians should advise low-prognosis patients to cease undergoing further ART attempts, as prior studies have been unable to establish such a threshold owing to their short duration(45, 50).

Low-prognosis patients exhibit substantial heterogeneity with respect to their ultimate outcomes, largely owing to differences in age, ovarian reserve test cut-off values, and other risk factors(25, 52-54). For this study, we utilized the POSEIDON criteria to stratify patients into four groups as a means of reducing such heterogeneity and better defining optimal ART treatment strategies for each of these patient subgroups. Based upon the observed increases in CLBRs over time and with increasing numbers of FET cycles, we recommend that low-prognosis patients in all POSEIDON subgroups extend their treatment for no more than 3.5 years or 6 FET cycles, with a minimum treatment duration of greater than 2 years or 3 FET cycles. In addition, patients in group 3 (younger expected poor responders) and group 4 (older expected poor responders) exhibited particularly pronounced benefits when extending the duration of treatment to 3.5 years or 6 FET cycles.

**Mechanisms underlying different cumulative live birth rates in low-prognosis women**

Age is the primary determining factor for CLBR among low-prognosis women. In our data, patients in group 1 (30.21±2.76) and group 3 (30.32±2.71) exhibited significantly higher CLBRs relative to those of the older patients of group 2 (38.01±2.83) and group 4 (39.37±3.38), irrespective of time or FET cycle count. The age threshold of 35 years is generally considered to represent a watershed with respect to changes in embryo quality and quantity. As women age, rates of embryo euploidy fall by 2.4% per year, while rates of blastocyst euploidy fall from 60% prior to age 35 to 30% after age 40, with corresponding reductions in the odds of implantation(55, 56). As such, after 5 FET cycles or 3.5 years, the optimal estimated CLBRs for young POSEIDON group 1 (91.7%, 80.1%) and group 3 (87.4%, 74.5%) patients were similar to those of normal women (92.9% or 78.8%), whereas these rates were substantially lower for older POSEIDON group 2 (67.3%, 60.1%) and group 4 (48.6%, 38.9%) patients.

Within patients of a similar age, ovarian reserve is the second most important determinant of CLBR among low-prognosis women. Variations in CLBR between POSEIDON patient subgroups are secondarily attributable to the quantitative parameters(45), in line with reports demonstrating that lower AMH levels and decreased ovarian responses are related to lower odds of a live birth among women of similar age (57-59). As such, while patients in both groups 1 and 3 were under 35 years of age, the CLBR of patients in group 1 (unexpected
poor responders) was significantly higher than that of patients in group 3 (expected poor responders). Similar phenomena have been observed in the older POSEIDON groups, with patients in group 2 (unexpected poor responders) exhibiting a higher CLBR than that of patients in group 4 (expected poor responders) irrespective of the duration of time or number of FET cycles.

Recent work also suggests that CLBRs rise significantly with the number of retrieved oocytes(60). This likely explained the observed increases in CLBRs in all four POSEIDON groups over 5 years or increasing numbers of FET cycles in this study, irrespective of patient age or ovarian reserve. However, there was substantial heterogeneity among these four POSEIDON groups, exhibiting differing levels of increases in CLBRs over time or with increasing FET cycles. Within 2-3.5 years or 4-6 FET cycles, the CLBRs in group 3 (younger expected poor responders) and group 4 (older expected poor responders) exhibited clearer increases in CLBRs relative to the other POSEIDON groups, likely owing to oocyte accumulation and effects being more substantially increased in these expected poor responders.

Conclusions

In conclusion, we herein conducted an analysis of CLBRs for women in different POSEIDON groups and controls over the course of up to 5 years or 9 FET cycles in order to provide a better clinical reference for low-prognosis women undergoing ART treatment. Patients in group 1 (younger unexpected poor responders) exhibited the highest CLBR within the 5-year or 9 FET cycle period, followed by group 3 (younger expected poor responders), group 2 (older unexpected poor responders), and group 4 (older unexpected poor responders) patients. While there were differences in CLBRs among these groups, the observed upward trends suggest that all low-prognosis women should undergo ART treatment for a minimum of 2 years or 3 FET cycles, with better outcomes over 3.5 years or 6 FET cycles, particularly for group 3 and group 4 patients. However, beyond those milestones, patients should consider ceasing to undergo further ART treatment. Together, these data provide new insight into how long low-prognosis women should seek to undergo ART treatment in an effort to improve their odds of a live birth.

Abbreviations

POR: Poor ovarian response; DOR: Diminished ovarian reserve; ART: Assited reproductive technology; CLBR: Cumulative live birth rate; ET: Fresh embryo transfer; FET: Frozen embryo transfer; ESHRE: European Society of Human Reproduction and Embryology; POSEIDON: Patient-Oriented Strategies Encompassing Individualized Oocyte Number; IVF: In vitro fertilization; ICSI: Intracytoplasmatic sperm injection; AFC: Antral follicle count; MPA: Medroxyprogesterone acetate; DYG: Duphaston; SD: Standard deviation; OPU: Ovum pick-up; PPOS: Progestin-primed ovarian stimulation; BMI: Body mass index; CI: Confidence interval; LBR: Live birth rate; AMH: Anti miillerian hormone.

Declarations

Acknowledgements
We gratefully acknowledge all the doctors, nurses and laboratory staffs employed in the department of assisted reproduction, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

Authors’ contributions

YPK and LW supervised the entire study, including the procedures, conception, design, and completion. DC and XS performed the acquisition of data, analysis of data. DC wrote the manuscript. YPK and LW revised the manuscript. All the authors take full responsibility for the work.

Funding

This work was supported by the National Natural Science Foundation of China (grant number: 81771533), the National Key Research and Development Program of China (grant number: 2018YFC1003000) and Elite Group Project of Shanghai Ninth People's Hospital (grant number: JY201801).

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethics Committee (Institutional Review Board) of Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine (No. 2017-017). The Ethics Committee of Shanghai Ninth People's Hospital (Institutional Review Board) waived the need for written informed consent due to the retrospective nature and patients’ data were used anonymously. All procedures performed in the study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References
1. Moolenaar LM, Mohiuddin S, Munro Davie M, Merrilees MA, Broekmans FJ, Mol BW, et al. High live birth rate in the subsequent IVF cycle after first-cycle poor response among women with mean age 35 and normal FSH. Reproductive biomedicine online. 2013;27(4):362–6.

2. Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL. The poor responder in IVF: is the prognosis always poor?: a systematic review. Human reproduction update. 2012;18(1):1–11.

3. Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? Hum Reprod. 2015;30(12):2703–7.

4. Giannelou P, Simopoulou M, Grigoriadis S, Makrakis E, Kontogeorgi A, Pantou A, et al. The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment. Diagnostics (Basel, Switzerland). 2020;10(9).

5. Humaidan P, La Marca A, Alviggi C, Esteves SC, Haahr T. Future Perspectives of POSEIDON Stratification for Clinical Practice and Research. Front Endocrinol (Lausanne). 2019;10:439.

6. Elizur SE, Lemer-Geva L, Levron J, Shulman A, Bider D, Dor J. Cumulative live birth rate following in vitro fertilization: study of 5,310 cycles. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2006;22(1):25–30.

7. Lintsen AM, Eijkemans MJ, Hunault CC, Bouwmans CA, Hakkaart L, Habbema JD, et al. Predicting ongoing pregnancy chances after IVF and ICSI: a national prospective study. Hum Reprod. 2007;22(9):2455–62.

8. Fukuda J, Kumagai J, Kodama H, Murata M, Kawamura K, Tanaka T. Upper limit of the number of IVF-ET treatment cycles in different age groups, predicted by cumulative take-home baby rate. Acta Obstet Gynecol Scand. 2001;80(1):71–3.

9. Stolwijk AM, Wetzels AM, Braat DD. Cumulative probability of achieving an ongoing pregnancy after in-vitro fertilization and intracytoplasmic sperm injection according to a woman's age, subfertility diagnosis and primary or secondary subfertility. Hum Reprod. 2000;15(1):203–9.

10. Olivius K, Friden B, Lundin K, Bergh C. Cumulative probability of live birth after three in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril. 2002;77(3):505–10.

11. Engmann L, Maconochie N, Bekir JS, Jacobs HS, Tan SL. Cumulative probability of clinical pregnancy and live birth after a multiple cycle IVF package: a more realistic assessment of overall and age-specific success rates? Br J Obstet Gynaecol. 1999;106(2):165–70.

12. Tan SL, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol. 1994;171(2):513–20.

13. Witsenburg C, Dieben S, Van der Westerlaken L, Verburg H, Naaktgeboren N. Cumulative live birth rates in cohorts of patients treated with in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril. 2005;84(1):99–107.

14. Guzick DS, Wilkes C, Jones HW, Jr. Cumulative pregnancy rates for in vitro fertilization. Fertil Steril. 1986;46(4):663–7.

15. Ke H, Chen X, Liu YD, Ye DS, He YX, Chen SL. Cumulative live birth rate after three ovarian stimulation IVF cycles for poor ovarian responders according to the bologna criteria. Journal of Huazhong University of
16. Li Y, Li X, Yang X, Cai S, Lu G, Lin G, et al. Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of in vitro Fertilization/Intracytoplasmic Sperm Injection. Front Endocrinol (Lausanne). 2019;10:642.

17. Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. N Engl J Med. 2009;360(3):236–43.

18. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017;108(3):393–406.

19. Shi W, Zhou H, Tian L, Zhao Z, Zhang W, Shi J. Cumulative Live Birth Rates of Good and Low Prognosis Patients According to POSEIDON Criteria: A Single Center Analysis of 18,455 Treatment Cycles. Front Endocrinol (Lausanne). 2019;10:409.

20. Li Z, Wang AY, Bowman M, Hammarberg K, Farquhar C, Johnson L, et al. Cumulative live birth rates following a ‘freeze-all’ strategy: a population-based study. Hum Reprod Open. 2019;2019(2):hoz004.

21. Toftager M, Bogstad J, Løssl K, Prætorius L, Zedeler A, Bryndorf T, et al. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Hum Reprod. 2017;32(3):556–67.

22. Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ~15,000 women. Fertil Steril. 2018;110(4):661-70.e1.

23. Yin H, Jiang H, He R, Wang C, Zhu J, Cao Z. Cumulative live birth rate of advanced-age women more than 40 with or without poor ovarian response. Taiwanese journal of obstetrics & gynecology. 2019;58(2):201–5.

24. Patrizio P, Vaiarelli A, Levi Setti PE, Tobler KJ, Shoham G, Leong M, et al. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reproductive biomedicine online. 2015;30(6):581–92.

25. Drakopoulos P, Bardhi E, Boudry L, Vaiarelli A, Makrigiannakis A, Esteves SC, et al. Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept. Therapeutic advances in reproductive health. 2020;14:2633494120941480.

26. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–24.

27. Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why. Front Endocrinol (Lausanne). 2018;9:461.

28. Busnelli A, Papaleo E, Del Prato D, La Vecchia I, Iachini E, Paffoni A, et al. A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Hum Reprod. 2015;30(2):315–22.
29. La Marca A, Grisendi V, Giuliani S, Sighinolfi G, Tirelli A, Argento C, et al. Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study. J Assist Reprod Genet. 2015;32(6):931–7.
30. Bozdog G, Polat M, Yarali I, Yarali H. Live birth rates in various subgroups of poor ovarian responders fulfilling the Bologna criteria. Reprod Biomed Online. 2017;34(6):639–44.
31. Poseidon G, Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452–3.
32. Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. F1000Res. 2016;5:2911.
33. Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, et al. The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. Front Endocrinol (Lausanne). 2019;10:814.
34. Drakopoulos P, Garcia-Velasco J, Bosch E, Blockeel C, de Vos M, Santos-Ribeiro S, et al. ICSI does not offer any benefit over conventional IVF across different ovarian response categories in non-male factor infertility: a European multicenter analysis. J Assist Reprod Genet. 2019;36(10):2067–76.
35. Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore). 2015;94(21):e909.
36. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229–37.
37. Xi Q, Tao Y, Qiu M, Wang Y, Kuang Y. Comparison Between PPOS and GnRHa-Long Protocol in Clinical Outcome with the First IVF/ICSI Cycle: A Randomized Clinical Trial. Clin Epidemiol. 2020;12:261–72.
38. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70 e3.
39. Huang J, Lu X, Xie Q, Lin J, Cai R, Kuang Y. Timing of frozen-thawed embryo transfer after controlled ovarian stimulation in a non-elective freeze-all policy. Ann Transl Med. 2019;7(23):752.
40. Shen X, Long H, Guo W, Xie Y, Gao H, Zhang J, et al. The ovulation trigger-OPU time interval of different ovarian protocols in ART: a retrospective study. Arch Gynecol Obstet. 2020;302(2):519–27.
41. Henkel RR, Schill WB. Sperm preparation for ART. Reprod Biol Endocrinol. 2003;1:108.
42. Cummins JM, Breen TM, Harrison KL, Shaw JM, Wilson LM, Hennessey JF. A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. Journal of in vitro fertilization and embryo transfer: IVF. 1986;3(5):284–95.
43. Du T, Chen H, Fu R, Chen Q, Wang Y, Mol BW, et al. Comparison of ectopic pregnancy risk among transfers of embryos vitrified on day 3, day 5, and day 6. Fertil Steril. 2017;108(1):108-16 e1.
44. Li J, Lin J, Yin M, Zhu Q, Kuang Y. The live birth and neonatal outcomes in the subsequent pregnancy among patients with adverse pregnancy outcomes in first frozen embryo transfer cycles. Arch Gynecol Obstet. 2020;302(3):731–40.

45. Leijdekkers JA, Eijkemans MJC, van Tilborg TC, Oudshoorn SC, van Golde RJT, Hoek A, et al. Cumulative live birth rates in low-prognosis women. Hum Reprod. 2019;34(6):1030–41.

46. Stolwijk AM, Hamilton CJ, Hollanders JM, Bastiaans LA, Zielhuis GA. A more realistic approach to the cumulative pregnancy rate after in-vitro fertilization. Hum Reprod. 1996;11(3):660–3.

47. Levi-Setti PE, Zerbetto I, Baggiani A, Zannoni E, Sacchi L, Smeraldi A, et al. An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria. Front Endocrinol (Lausanne). 2019;10:282.

48. Stojkovska S, Dimitrov G, Stamenkovska N, Hadzi-Lega M, Petanovski Z. Live Birth Rates in Poor Responders’ Group after Previous Treatment with Autologous Platelet-Rich Plasma and Low Dose Ovarian Stimulation Compared with Poor Responders Used Only Low Dose Ovarian Stimulation Before in Vitro Fertilization. Open access Macedonian journal of medical sciences. 2019;7(19):3184–8.

49. Datta AK, Maheshwari A, Felix N, Campbell S, Nargund G. Mild versus conventional ovarian stimulation for IVF in poor responders: a systematic review and meta-analysis. Reproductive biomedicine online. 2020;41(2):225–38.

50. Gu F, Ruan S, Luo C, Huang Y, Luo L, Xu Y, et al. Can repeat IVF/ICSI cycles compensate for the natural decline in fertility with age? an estimate of cumulative live birth rates over multiple IVF/ICSI cycles in Chinese advanced-aged population. Aging. 2021;13.

51. McLemon DJ, Maheshwari A, Lee AJ, Bhattacharya S. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. Hum Reprod. 2016;31(3):572–81.

52. Busnelli A, Somigliana E. Prognosis and cost-effectiveness of IVF in poor responders according to the Bologna Criteria. Minerva ginecologica. 2018;70(1):89–98.

53. Romito A, Bardhi E, Errazuriz J, Blockeel C, Santos-Ribeiro S, Vos M, et al. Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates. Front Endocrinol (Lausanne). 2020;11:208.

54. Xu B, Chen Y, Geerts D, Yue J, Li Z, Zhu G, et al. Cumulative live birth rates in more than 3,000 patients with poor ovarian response: a 15-year survey of final in vitro fertilization outcome. Fertil Steril. 2018;109(6):1051–9.

55. Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril. 2014;101(4):967–73.

56. Liu K, Case A. Advanced reproductive age and fertility. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique et gynecologie du Canada: JOGC. 2011;33(11):1165–75.

57. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26(7):1768–74.
58. Hamdine O, Eijkemans MJC, Lentjes EGW, Torrance HL, Macklon NS, Fauser B, et al. Antimullerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization. Fertil Steril. 2015;104(4):891-8 e2.

59. Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including approximately 15,000 women. Fertil Steril. 2018;110(4):661-70 e1.

60. Devesa M, Tur R, Rodríguez I, Coroleu B, Martínez F, Polyzos NP. Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women ≥38 years old. Hum Reprod. 2018;33(11):2010–7.

Tables

Table 1

Demographics and baseline characteristics of the participants in the first oocyte retrieval cycle
| Group          | POSEIDON group | Control group | P value |
|---------------|----------------|---------------|---------|
| Group1        | Younger unexpected poor responders | Group1        |         |
| Group2        | Older unexpected poor responders  | Group2        |         |
| Group3        | Younger expected poor responders  | Group3        |         |
| Group4        | Older expected poor responders    | Group4        |         |
| Group5        | Younger expected poor responders  | Group5        |         |
| Younger       | Older       |             |         |
| Patients (n)  | 4470        | 2270         | 1110    | 1095    | 8753     |
| Age of female | 30.21±2.76a | 38.01±2.83b  | 30.32±2.71a,d | 39.37±3.38c | 30.44±3.85d | <0.05  |
| Percentage of age | a            | b            | c        | d        | e        | <0.05  |
| ≤30           | 2234 (50.0%) | 0 (0.0%)     | 541 (48.7%) | 0 (0.0%) | 4760 (54.4%) |         |
| >30, ≤35      | 2236 (50.0%) | 494 (21.8%)  | 569 (51.3%) | 141 (12.9%) | 3103 (35.5%) |         |
| >35, ≤40      | 0 (0.0%)     | 1360 (59.9%) | 0 (0.0%)  | 564 (51.5%) | 796 (9.1%) |         |
| >40           | 0 (0.0%)     | 416 (18.3%)  | 0 (0.0%)  | 390 (35.6%) | 94 (1.1%) |         |
| AFC           | 11.17±5.77a | 8.99±4.09b   | 2.19±1.65c | 2.51±1.32c | 15.24±6.21d | <0.05  |
| Percentage of AFC | a            | b            | c        | c        | d        | <0.05  |
| <4            | 0 (0.0%)     | 0 (0.0%)     | 750 (67.6%) | 776 (70.9%) | 0 (0.0%) |         |
| ≥4, <10       | 2185 (48.9%) | 1502 (66.2%) | 360 (32.4%) | 319 (29.1%) | 1444 (16.5%) |         |
| ≥10           | 2285 (51.1%) | 768 (33.8%)  | 0 (0.0%)  | 0 (0.0%)  | 7309 (83.5%) |         |
| Oocytes retrieved in the first cycle (n) | 5.97±2.31a | 5.27±2.34b | 7.07±6.67c | 3.29±3.05d | 16.84±6.57e | <0.05  |
| Type of infertility | a            | b            | c        | d        | e        | <0.05  |
| Primary       | 2673(59.8%)  | 848(37.4%)   | 713(64.2%) | 383(35.0%) | 5059(57.8%) |         |
| Secondary     | 1797(40.2%)  | 1422(62.6%)  | 397(35.8%) | 712(65.0%) | 3694(42.2%) |         |
| Main etiology | a            | b            | c        | d        | e        | <0.05  |
| Female        | 460 (10.3%)  | 240 (10.6%)  | 94 (8.5%) | 69 (6.3%) | 1076 (12.3%) |         |
| Male          | 2945         | 1401         | 770 (69.4%) | 741 (67.7%) | 5567     |         |
| Year of treatment | POSEIDON | Control | POSEIDON | Control | POSEIDON | Control | POSEIDON | Control |
|-------------------|----------|---------|----------|---------|----------|---------|----------|---------|
| 2013-2014         | 1160 (26.0%) | 526 (23.2%) | 309 (27.8%) | 304 (27.8%) | 2248 (25.7%) |       |
| 2015              | 859 (19.2%) | 375 (16.5%) | 258 (23.2%) | 180 (16.4%) | 1821 (20.8%) |       |
| 2016              | 1349 (30.2%) | 730 (32.2%) | 362 (32.6%) | 348 (31.8%) | 2188 (25.0%) |       |
| 2017              | 683 (15.3%) | 353 (15.6%) | 111 (10.0%) | 172 (15.7%) | 1353 (15.5%) |       |
| 2018              | 419 (9.4%) | 286 (12.6%) | 70 (6.3%) | 91 (8.3%) | 1143 (13.1%) |       |

| Values are presented as mean ± SD or number (percentage). The differences were considered statistically significant when the p-value was less than 0.05. Different alphabets represent significant differences between groups. AFC, antral follicle count; BMI, body mass index. |
|--------------------------------------------------------------------------------------------------|

### Table 2

Ovarian Stimulation Characteristics and Cumulative live birth rates within POSEIDON and control groups
|                                | POSEIDON group |                                           |                                           |                                           | Control group | P-value |
|--------------------------------|----------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|---------------|---------|
|                                | Group1         | Group2                                     | Group3                                     | Group4                                     | Group5         |         |
|                                | Younger        | Older                                      | Younger                                    | Older                                      |               |         |
|                                | unexpected     | unexpected                                 | expected                                  | expected                                  |               |         |
|                                | poor           | poor                                       | responders                                 | responders                                 |               |         |
|                                | responders      | responders                                 |                                             |                                             |               |         |
| Patients (n)                   | 4470           | 2270                                       | 1110                                       | 1095                                       | 8753          |         |
| Oocyte retrieval cycles (n)    | 1.33±0.64a     | 1.54±0.89b                                 | 1.55±0.94b                                 | 1.97±1.33c                                 | 1.11±0.38d    | 0.05    |
| Retrieved oocytes (n)          | 5.97±2.31a     | 5.27±2.34b                                 | 7.07±6.67c                                 | 3.29±3.05d                                 | 16.84±6.57e   | 0.05    |
| Retrieved Oocytes / AFC (%)    | 58.02%         | 62.96%                                     | 199.21%                                    | 99.31%                                     | 109.28%       | 0.05    |
| Cycles of 0 oocyte Retrieved (%)| 25 (0.4%)a    | 12 (0.3%)a                                 | 32 (1.9%)b                                 | 51 (2.4%)b                                 | 0 (0.0%)c     | 0.05    |
| Insemination method            | a a            | b b                                        | c c                                        | d d                                        | e e           | 0.05    |
|                                | IVF            | ICSI                                        | IVF/ICSI                                   | IVF/ICSI                                   |               |         |
|                                | 2878 (64.6%)   | 1486 (65.8%)                               | 781 (70.9%)                                | 752 (69.8%)                                | 5069 (58.0%)  |         |
|                                | ICSI           | 988 (22.2%)                                | 572 (25.3%)                                | 235 (21.3%)                                | 290 (26.9%)   |         |
|                                | IVF/ICSI       | 587 (13.2%)                                | 201 (8.9%)                                 | 86 (7.8%)                                  | 36 (3.3%)     |         |
|                                | 2PN embryos per oocyte retrieval cycle (n) | 3.86±2.08a                                | 3.44±1.95b                                 | 4.47±4.26c                                 | 2.16±2.13d    | 0.05    |
|                                | Good quality embryos per oocyte retrieval cycle (n) | 2.15±1.71a                                | 1.98±1.55b                                 | 2.38±2.59c                                 | 1.27±1.39d    | 0.05    |
|                                | FET cycles (n) | 1.46±0.81a                                | 1.58±0.92b                                 | 1.47±0.78ab                                | 1.54±0.94ab   | 1.57±0.88b | 0.05    |
|                                | Transplanted embryos (n) | 2.31±1.61a                                | 2.50±1.88b                                 | 2.27±1.70a                                 | 2.01±1.74c    | 3.08±1.88d | 0.05    |
|                                | CLBR over 2 years |                                         |                                            |                                            |               |         |
|               | Optimistic 95%CI  | Conservative 95%CI  | CLBR over 5 years |
|---------------|------------------|---------------------|-------------------|
|               | 0.76 (0.74-0.77) | 0.64 (0.62-0.65)   |                   |
|               | 0.55 (0.53-0.58) | 0.42 (0.40-0.44)   |                   |
|               | 0.67 (0.63-0.70) | 0.55 (0.52-0.58)   |                   |
|               | 0.36 (0.32-0.39) | 0.26 (0.23-0.29)   |                   |
|               | 0.76 (0.75-0.77) | 0.70 (0.70-0.71)   |                   |
|               | 0.001            | 0.001               |                   |

**Figures**

CLBR of FET cycles in the low prognosis patients (2013-2019)

n=19273

Excluded
n=1575, with uncomplete data

Total patients
n=17698

POSEIDON criteria
n=8945

**Figures 1**

Study population flow chart
Low-prognosis women were classified into four groups as per the POSEIDON classification, with the control group consisting of normal and good responders.

**Figure 2**

**Cumulative live birth curves for low-prognosis women over 5 years**

Two approaches were applied to depict cumulative live birth curves over 5 years: (A) an optimistic method (a life table analysis) and (B) a conservative method (a competing risk analysis). The number of risks and the pairwise comparisons between different POSEIDON groups are listed below the CLBR curves.
### Figure 3

**Cumulative live birth curves for low-prognosis women over 9 FET cycles**

Two approaches were applied to depict cumulative live birth curves over 9 FET cycles: (A) an optimistic method (a life table analysis) and (B) a conservative method (a competing risk analysis). The number of risks and the pairwise comparison between different POSEIDON groups are listed below the CLBR curves.